 SAN DIEGO, Calif. and SUZHOU and SHANGHAI, China , May 26, 2022 PRNewswire -- Gracell Biotechnologies Inc. Gracell or the Company, NASDAQ: GRCL, a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that it will present updated clinical data from a multicenter investigator-initiated trial IIT evaluating GC012F, the companys B-cell maturation antigen BCMA and CD19 dual-targeting CAR-T candidate, for the treatment of relapsedrefractory multiple myeloma RRMM in an oral abstract presentation at the 2022 American Society of Clinical Oncology ASCO 2022 Annual Meeting. 